Get the Stockscreener App
1.18
14.56%
0.15
Pre-market:
1.18
Entera Bio Ltd stock is traded at $1.18, with a volume of 285.10K.
It is up +14.56% in the last 24 hours and down -25.32% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.03
Open:
$1.09
24h Volume:
285.10K
Relative Volume:
1.35
Market Cap:
$54.11M
Revenue:
$124.00K
Net Income/Loss:
$-10.78M
P/E Ratio:
-4.8242
EPS:
-0.2446
Net Cash Flow:
$-7.36M
1W Performance:
-11.94%
1M Performance:
-25.32%
6M Performance:
-34.08%
1Y Performance:
-37.23%
1-Day Range:
$1.04
$1.25
1-Week Range:
$0.9801
$1.32
52-Week Range:
$0.9801
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.18 | 54.11M | 124.00K | -10.78M | -7.36M | -0.2446 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
S P Trends: Should I invest in Entera Bio Ltd before earnings2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market - TradingView
If You Invested $1,000 in Entera Bio Ltd (ENTX) - Stock Titan
What pushed Entera Bio (ENTX) to rally nearly 16% after hours - MSN
Entera Bio (ENTX) Expected to Announce Earnings on Friday - MarketBeat
Analyst Upgrade: Is Entera Bio Ltd stock risky to hold now2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trend Review: Should I invest in Entera Bio Ltd before earnings2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Energy Moves: Can Entera Bio Ltd weather a recession2026 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline f - GuruFocus
Performance Recap: Is Entera Bio Ltd stock risky to hold now2026 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy - TipRanks
Entera Bio (NASDAQ:ENTX) Director Geno Germano Purchases 20,000 Shares - MarketBeat
Insider Buying: Geno Germano Acquires Additional Shares of Enter - GuruFocus
Entera Bio (ENTX) director buys 20,000 shares in open market - Stock Titan
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Director Sean Ellis buys 10,000 Entera Bio (ENTX) shares on market - Stock Titan
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX) - TipRanks
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Stocktwits
Entera Bio (NASDAQ:ENTX) Stock Price Down 3%Here's What Happened - MarketBeat
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Bitget
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Submits Streamlined Phase 3 Plan for EB613 - TipRanks
Entera Bio submits streamlined Phase 3 protocol for EB613, seeks 12-month hip BMD primary endpoint - TradingView
Entera Bio (NASDAQ: ENTX) refines EB613 Phase 3 osteoporosis trial timeline - Stock Titan
Entera Bio submits streamlined phase 3 protocol to initiate registrational program for EB613 in postmenopausal women with osteoporosis - marketscreener.com
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate - GlobeNewswire
Enterprise value of Entera Bio Ltd. – HAM:5DT - TradingView
Net margin % of Entera Bio Ltd. – HAM:5DT - TradingView
Debt to equity ratio of Entera Bio Ltd. – HAM:5DT - TradingView
ENTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ENTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Short Bowel Syndrome Market: High-Growth Opportunities for Investors to 2034DelveInsight - openPR.com
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
Entera Bio CEO to join Leerink 2026 healthcare fireside chat - Stock Titan
Buyback Watch: Is Entera Bio Ltd stock risky to hold nowTrade Ideas & Low Volatility Stock Suggestions - baoquankhu1.vn
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woma - GuruFocus
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX) - TipRanks
Nasdaq Moves: Is BHRPRB impacted by rising ratesJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
ENTXEntera Bio Ltd Latest Stock News & Market Updates - Stock Titan
Will Entera Bio Ltd. stock see insider buyingJuly 2025 Pullbacks & Accurate Buy Signal Alerts - mfd.ru
Entera Bio names former Pfizer executive Geno Germano as board chair - MSN
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours - Finviz
Entera Bio (ENTX) director buys 5,000 shares in open market trade - Stock Titan
Is Entera Bio Ltd. a good stock for dollar cost averaging2025 Support & Resistance & Verified Technical Trade Signals - mfd.ru
Will Entera Bio Ltd. stock outperform growth indexesEarnings Summary Report & Free High Accuracy Swing Entry Alerts - mfd.ru
Is Entera Bio Ltd. stock risky to hold nowWeekly Investment Summary & Growth Oriented Trading Recommendations - mfd.ru
Aug Momentum: Can Entera Bio Ltd deliver consistent dividendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire Inc.
Why Entera Bio Ltd. stock could rally in 2025Chart Signals & Expert Approved Momentum Trade Ideas - mfd.ru
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):